Return to content in this issue
Role of Drug Hypersensitivity in the Cutaneous Manifestations of SARS-CoV-2 Infection
Solano-Solares E1*, Chica-Guzmán V1*, Pérez-Allegue I1, Cabrera-Hernández R1, Fernández-Guarino M2, Fernández-Nieto D2, Moreno-García-del-Real C3, de-Andres-Martin A4, García-Bermejo L5, González-de-Olano D1,6**, de-la-Hoz-Caballer B1,6**
1Allergology Department, Hospital Universitario Ramón y Cajal, IRYCS, Madrid, Spain
2Dermatology Department Hospital Universitario Ramón y Cajal, IRYCS, Madrid, Spain
3Histopathology Department Hospital Universitario Ramón y Cajal, IRYCS, Madrid, Spain
4Immunology Department Hospital Universitario Ramón y Cajal, IRYCS, Madrid, Spain
5Biomarkers and Therapeutic Targets Group, RedinRen, Hospital Universitario Ramón y Cajal, IRYCS, Madrid, Spain
6Spanish Thematic Network and Co-operative Research Centres, ARADyAL, Spain
*Both authors contributed equally and should be considered first authors.
**Both authors should be considered senior authors.
J Investig Allergol Clin Immunol 2022; Vol 32(3)
: 218-220
doi: 10.18176/jiaci.0744
Key words: Cutaneous manifestations, Drug provocation test, First wave, SARS-CoV-2, Drug hypersensitivity
| Title | Type | Size | |
|---|---|---|---|
 |
doi10.18176_jiaci.0744_material-suppl_figure.pdf | 137.88 Kb | |
|
doi10.18176_jiaci.0744_material-suppl_table.pdf | 208.34 Kb |
